Citadel Advisors
TCRT icon

Citadel Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Citadel Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,309
Closed -$30.1K – 15232
2024
Q2 		$30.1K Buy
4,309
+682
+19% +$8.14K ﹤0.01% 12268
2024
Q1 		$65.6K Buy
3,627
+2,793
+335% +$55.8K ﹤0.01% 11894
2023
Q4 		$8.85K Sell
834
-5
-0.6% -$60 ﹤0.01% 13190
2023
Q3 		$16.6K Sell
839
-438
-34% -$18.9K ﹤0.01% 12772
2023
Q2 		$97.7K Sell
1,277
-144
-10% -$11.6K ﹤0.01% 10977
2023
Q1 		$134K Buy
1,421
+192
+16% +$18.3K ﹤0.01% 10819
2022
Q4 		$120K Buy
1,229
+446
+57% +$64.6K ﹤0.01% 10971
2022
Q3 		$202K Sell
783
-182
-19% -$52.9K ﹤0.01% 10384
2022
Q2 		$179K Sell
965
-267
-22% -$25.5K ﹤0.01% 10816
2022
Q1 		$121K Sell
1,232
-1,331
-52% -$171K ﹤0.01% 12075
2021
Q4 		$419K Sell
2,563
-70
-3% -$15.4K ﹤0.01% 10106
2021
Q3 		$719K Buy
2,633
+545
+26% +$167K ﹤0.01% 9003
2021
Q2 		$827K Buy
2,088
+265
+15% +$124K ﹤0.01% 8853
2021
Q1 		$984K Buy
1,823
+380
+26% +$237K ﹤0.01% 8158
2020
Q4 		$545K Buy
1,443
+16
+1% +$6.36K ﹤0.01% 7975
2020
Q3 		$540K Sell
1,427
-362
-20% -$160K ﹤0.01% 7161
2020
Q2 		$880K Buy
1,789
+63
+4% +$28.1K ﹤0.01% 6058
2020
Q1 		$634K Buy
1,726
+691
+67% +$358K ﹤0.01% 6095
2019
Q4 		$733K Buy
1,035
+62
+6% +$42.7K ﹤0.01% 6162
2019
Q3 		$625K Buy
973
+384
+65% +$305K ﹤0.01% 6377
2019
Q2 		$515K Sell
589
-297
-34% -$204K ﹤0.01% 6782
2019
Q1 		$512K Sell
886
-625
-41% -$261K ﹤0.01% 6750
2018
Q4 		$424K Buy
1,511
+644
+74% +$255K ﹤0.01% 6664
2018
Q3 		$416K Buy
867
+177
+26% +$75.9K ﹤0.01% 6994
2018
Q2 		$313K Buy
690
+373
+118% +$237K ﹤0.01% 7143
2018
Q1 		$186K Sell
317
-245
-44% -$153K ﹤0.01% 7411
2017
Q4 		$349K Buy
562
+249
+80% +$179K ﹤0.01% 6205
2017
Q3 		$288K Sell
313
-23
-7% -$20.4K ﹤0.01% 6133
2017
Q2 		$313K Sell
336
-193
-36% -$189K ﹤0.01% 5839
2017
Q1 		$503K Sell
529
-57
-10% -$53.1K ﹤0.01% 5003
2016
Q4 		$470K Sell
586
-21
-3% -$18.9K ﹤0.01% 5000
2016
Q3 		$513K Buy
607
+183
+43% +$147K ﹤0.01% 4813
2016
Q2 		$349K Sell
424
-97
-19% -$106K ﹤0.01% 4995
2016
Q1 		$580K Buy
521
+262
+101% +$268K ﹤0.01% 4196
2015
Q4 		$323K Sell
259
-277
-52% -$458K ﹤0.01% 5113
2015
Q3 		$724K Buy
536
+66
+14% +$109K ﹤0.01% 4257
2015
Q2 		$846K Buy
470
+103
+28% +$160K ﹤0.01% 4202
2015
Q1 		$593K Buy
367
+244
+198% +$362K ﹤0.01% 4659
2014
Q4 		$93K Buy
123
+97
+373% +$51.5K ﹤0.01% 6704
2014
Q3 		$10K Sell
26
-77
-75% -$37.1K ﹤0.01% 7755
2014
Q2 		$62K Sell
103
-52
-34% -$29K ﹤0.01% 6602
2014
Q1 		$106K Sell
155
-124
-44% -$83.1K ﹤0.01% 6143
2013
Q4 		$182K Buy
279
+102
+58% +$60.7K ﹤0.01% 5124
2013
Q3 		$105K Sell
177
-95
-35% -$42.8K ﹤0.01% 5319
2013
Q2 		$86K Buy
+272
New +$75.5K ﹤0.01% 5322

Other funds holding TCRT

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citadel Advisors's TCRT Position: Q1 2026 in Review

Citadel Advisors opened a new position in Alaunos Therapeutics (TCRT) in Q1 2026: 10,519 shares worth $30.1K. The stake represents ﹤0.01% of the portfolio and ranks #12570 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in TCRT as recently as Q2 2024.

Citadel Advisors first reported a position in TCRT in Q2 2013 and has held it in 40 quarters since. The position peaked at $3.94M in Q2 2016. 29 funds tracked by Wall St. Rank hold TCRT as of Q1 2026.

  • Citadel Advisors held 10,519 shares of Alaunos Therapeutics worth $30.1K as of Q1 2026.
  • Alaunos Therapeutics was a new Citadel Advisors position in Q1 2026.
  • Alaunos Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12570 holding.
  • Citadel Advisors first reported a position in Alaunos Therapeutics in Q2 2013 and has held it in 40 quarters since.
  • Citadel Advisors's Alaunos Therapeutics position peaked at $3.94M in Q2 2016.
  • 29 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.